Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1021-1040 of 1,743 trials

GTX-102 for Children with Angelman Syndrome

We are studying whether GTX-102 can improve cognitive function and other skills in children with deletion-type Angelman Syndrome. The trial also aims to evaluate the safety of this new treatment.

Angelman's Syndrome>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Azithromycin for Hospitalized Children with Asthma Symptoms

We are studying whether a three-day treatment with azithromycin helps young children aged 1-5 years who are hospitalized due to asthma-like symptoms. This research may lead to better, personalized treatments based on individual responses.

Childhood Asthma>2 yearsEfficacy phase (II)Investigational MedicinesPediatricsPulmonology

Endometrial Stromal Sarcoma: Aromatase Inhibitor Treatment Study

We are comparing the effects of stopping versus continuing aromatase inhibitors in patients with advanced low-grade endometrial stromal sarcoma. This study aims to find out which approach may help patients live longer without disease progression.

Low-Grade Endometrial Stroma Sarcoma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Gastrointestinal Stromal Tumors: Imatinib Treatment Study

We are exploring whether continuing or stopping imatinib treatment after 10 years benefits patients with advanced GISTs. The study looks at health outcomes like survival rates and quality of life.

Locally Advanced or Metastatic Gastrointestinal Stromal Tumors>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Mantle Cell Lymphoma: Ibrutinib and Venetoclax Study

We are studying the effects of Ibrutinib alone and in combination with Venetoclax in patients with untreated mantle cell lymphoma. The goal is to see how well these treatments reduce disease levels in the body.

Untreated Mantle Cell Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Infectious Pulmonary Endotheliopathy: Iloprost Infusion Study

We are investigating whether a continuous infusion of iloprost can help reduce the risk of death in mechanically ventilated patients with infectious pulmonary issues. This study compares the treatment to a placebo to assess its effectiveness.

Respiratory FailureInfectious Pulmonary Endotheliopathy>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Protecting Children from Radiation-Induced Hypothyroidism

We are studying whether TSH suppression during radiation therapy can lower the risk of hypothyroidism in children with medulloblastoma and lymphomas. This trial also examines any changes in thyroid tissue after treatment.

Hodgkin and Non-Hodgkin LymphomaMedulloblastoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesEndocrinologyOncology

IgA Nephropathy: Hydroxychloroquine Study

We are studying whether Hydroxychloroquine can help slow kidney function decline in patients with IgA Nephropathy. This trial focuses on those with high levels of protein in their urine despite current treatments.

IgA Nephropathy>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicineNephrology

Cardio Renal Syndrome: Peritoneal Ultrafiltration Treatment

We are studying whether Peritoneal Ultrafiltration can help prevent heart failure worsening in patients with Cardio Renal Syndrome. The trial also looks at improvements in health and quality of life.

Congestive Heart Failure>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCardiologyInternal MedicineNephrology

Wiskott-Aldrich Syndrome: Gene Therapy Follow-Up

We are monitoring the long-term safety of a gene therapy in patients with Wiskott-Aldrich Syndrome who received a specific stem cell treatment. This study helps us understand how the therapy affects their health over time.

Wiskott-Aldrich Syndrome>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematology

Fosfomycin: New Extended Infusion Method

We are studying a new way to give fosfomycin to see if it improves how the body absorbs the medication. This trial is for individuals needing antibiotic treatment.

Healthy Participants>2 yearsSafety phase (I)Infectious Diseases

Bladder Cancer: Neoadjuvant Chemotherapy Study

We are testing whether bladder instillation of neoadjuvant chemotherapy can help prevent recurrence in patients with non-muscle-invasive bladder cancer. This study compares it to standard treatment to assess effectiveness and side effects.

Non-muscle invasive bladder cancer>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Anticoagulant Treatments for Intra-Cardiac Thrombus: The ARGONAUT Trial

We are comparing a new direct oral anticoagulant with a standard vitamin K antagonist in patients with intra-cardiac thrombus. The goal is to see which treatment better reduces complications and promotes thrombus regression.

Intracardiac Thrombus>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

BCR-ABL1+ Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib, alone or with Nilotinib, for adults with BCR-ABL1+ Chronic Myeloid Leukemia. The goal is to see if this treatment helps achieve better disease control and improves quality of life.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteHematologyOncology

Colon Cancer: HIPEC with Mitomycin-C Study

We are investigating whether adding a special chemotherapy during surgery helps prevent cancer recurrence in patients with colon cancer that has spread to the abdomen. This study compares outcomes for those receiving this treatment versus standard care.

Peritoneal Metastases of Colorectal Cancer>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesOncology

Pemigatinib for Solid Tumors with FGFR Alterations

We are studying whether pemigatinib can help patients with recurrent or metastatic solid tumors that have a specific gene change. The trial aims to assess its effects on tumor growth and overall patient health.

Recurrent or Metastatic Solid Cancer with FGFR Alterations>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Multiple Myeloma: Venetoclax and Dexamethasone Study

We are investigating whether a combination of venetoclax and dexamethasone is effective for patients with relapsed and refractory multiple myeloma who have the translocation (11;14). This study aims to find out if this treatment can improve outcomes for these patients.

Multiple Myeloma>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesHematologyOncology

Pancreatic Cancer: CEB-01 Treatment Study

We are exploring a new treatment called CEB-01 for people with pancreatic cancer to see how safe it is and if it may help improve their condition.

Pancreatic Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

Acute Myeloid Leukemia: Ivosidenib, Azacitidine, and Venetoclax Study

We are investigating whether adding venetoclax to ivosidenib and azacitidine helps patients with newly diagnosed IDH1-mutated AML who cannot undergo intensive chemotherapy. The goal is to see if this combination improves survival and remission rates.

Acute Myeloid Leukemia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOncology

Septic Shock: Landiolol Infusion Study

We are investigating whether Landiolol can improve blood flow and heart function in patients with septic shock. This study compares its effects to standard treatments for managing rapid heart rates.

Microcirculatory Abnormalities in Septic Shock>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInfectious Diseases